These mutations lock the RAS protein in a constitutively active GTP-bound state, leading to ligand-independent activation of downstream effector pathways, including RAF-MEK-ERK and PI3K-AKT, thereby promoting tumor cell proliferation and survival. The gene discussed is PIK3CA; the disease is neoplasm.